Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
Latest Information Update: 23 Aug 2024
At a glance
- Drugs Ivarmacitinib (Primary) ; SHR-2554 (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 21 Aug 2024 Status changed from not yet recruiting to recruiting.
- 30 Jul 2024 New trial record